Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating income | -$82.9M | -$169M |
| Net income | -$77.6M | -$161M |
| EPS (diluted) | -$105.38 | -$18.56 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$78.8M | -$138M |
| Capital expenditures | $770K | $473K |
| Free cash flow | -$79.6M | -$139M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $38.3M | $46.7M |
| Total assets | $137M | $480M |
| Total liabilities | $21.7M | $21.1M |
| Shareholders' equity | -$194M | $458M |
| Retained earnings | -$199M | -$361M |
| Shares (wtd avg diluted) | 736K | 8.68M |
Every figure is extracted from MapLight Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.